Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GRAIL Inc (GRAL)
NASDAQ:GRAL
Holding GRAL?
Track your performance easily
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-$51.05Same Quarter Last Year
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: 21.60%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected strong revenue growth and improved financial performance, driven by increased demand for the Galleri test. However, ongoing net losses and future revenue growth constraints due to lack of broad reimbursement temper the positive outlook. The company's strategic focus on FDA approval and reimbursement is critical for future scalability.Company Guidance
During the GRAIL Q3 2024 earnings call, the executives provided guidance highlighting several key metrics. They reported a strong revenue of $28.7 million, representing a 38% increase compared to the same quarter in 2023. The company sold approximately 32,600 Galleri tests in this quarter, with screening revenue rising by 52% year-over-year. Despite a net loss of $125.7 million, this marked an 86% improvement from Q2 2023. The non-GAAP adjusted gross profit was $11.8 million, a 68% increase compared to Q3 2023, while the adjusted EBITDA improved by 14% to a negative $108.2 million. GRAIL also narrowed its 2024 Galleri sales growth guidance to between 40% and 50% and noted a reduced cash burn expectation for the second half, down from $250 million to $220 million. With a cash position of $853.6 million, the company expects its cash reserves to last until 2028, focusing on seeking FDA approval for Galleri and pursuing broad reimbursement.Strong Revenue Growth
Third quarter revenue was $28.7 million, up $7.9 million or 38% compared to Q3 2023. Screening revenue increased by 52% year-over-year.
Galleri Test Sales
Approximately 32,600 Galleri tests were sold in the third quarter, despite it being historically the slowest quarter due to summer holidays.
Improved Financial Performance
Net loss improved by 86% compared to Q2 2023, and adjusted gross profit increased by 68% year-over-year.
Cash Position and Reduced Cash Burn
Ended the quarter with a cash position of $853.6 million. Reduced cash burn guidance for the second half of the year from $250 million to $220 million.
Upcoming Product and Study Milestones
Launch of the next version of the Galleri test by the end of the year, and ongoing enrollment in the Galleri-Medicare REACH study.
---
GRAL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GRAL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $15.09 | $15.92 | +5.50% |
| Aug 13, 2024 | $15.84 | $15.39 | -2.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GRAIL Inc (GRAL) report earnings?
GRAIL Inc (GRAL) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is GRAIL Inc (GRAL) earnings time?
GRAIL Inc (GRAL) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GRAL EPS forecast?
Currently, no data Available
---